Clinical Trial Update: Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose decitabine in myelodysplastic syndromes after azacitidine failure; the study was terminated with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2011-02-21